The SynapTau team is thrilled to announce the publication of our collaborative work. This has been an incredible partnership, and we are delighted to share our findings in the journal Life Science Alliance! In this paper, we demonstrated that parenchymal border macrophages (PBMs) function impedes tau pathology and tau-mediated neurodegeneration, while tau pathology promotes PBM dysfunction associated with impaired CSF flow. Our results identify PBMs as novel cellular regulators of tau pathology and tau-mediated neurodegeneration.

The GlioME Team has new publication out in International Journal of Molecular Sciences as part of the Special Issue « Emerging Therapies for Glioblastoma ». This article deals with one of the team’s key issues, the gangliosides recognized by the A2B5 antibody and used as biomarker of cancer stem cells (CSC) in glioblastoma human brain tumours. To tackle these CSC known to be resistant to conventional treatment, the GlioME team aimed to better understand the effect of neuraminidase administration that removes A2B5, on an organotypic three-dimensional glioblastoma model.

Since the first event in Marseille in 2013, initiated by François Devred and Stéphane Honoré, the French microtubule network has been organizing colloquia bringing together researchers, post-docs and students from more than 34 laboratories, every 2 years in a different city. After Grenoble (2015), Versailles (2017), and Rennes (2019), the fifth edition of the congress of french scientists working on microtubules took place on June 29 and 30, 2023 in Montpellier. 

The occasion for José Luis to present the team's work on Snake venom myotoxins as microtubule-targeting peptides. 

The GlioME team and the PETRA platform welcomed two BUT students, Ludivine Rouillon and Emilie Louat, for their end-of-year internship.

Their internship ended with a presentation of their work as posters entitled: "Développement d'un modèle pré-clinique 3D de tumoroïdes dérivé de tumeurs du SNC pour l'étude de molécules thérapeutiques" and "Analyse de l'expression de la protéine AP après traitement au témozolomide ou radiothérapie dans le glioblastome".